Truqap could fill a prostate cancer gap
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
Kyowa buys into menin, but it's not Syndax's
Syndax scored the first menin approval, but Kura is first with a licensing deal.
Jefferies 2024 – Cargo tries again with an old idea
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
